NCT04423874 The Effect of Exposure to Aversive Non-verbal Vocalizations on Pain Tolerance
| NCT ID | NCT04423874 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2022-05-25 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 104 participants in total. It began in 2022-05-25 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Humans produce non-verbal vocalizations (shouting, growling, screaming), laughter, ...) in various contexts that are likely to perform biological functions. and important social issues. Yet despite their importance in the human vocal repertoire, the mechanisms and functions of non-verbal vocalizations remain little studied and poorly understood including in humans. In this context, the investigators wish to examine how the perception of vocalizations non-verbal aversive behaviours influence pain tolerance in healthy adults.
Eligibility Criteria
Inclusion Criteria: * Participant in good health * Affiliated or entitled participant in a social security scheme * Participant who received informed information about the study and co-signed, with the investigator, a consent to participate in the study Exclusion Criteria: * Chronic pain * High blood pressure or poor circulation * Cardiac or vascular disease, or a heart condition (including symptoms of Raynaud's syndrome) * Allergy or hypersensitivity to cold * Diabetes * Epilepsy * Pregnancy * Recent serious injury * Neurological or psychiatric condition known to affect pain tolerance (e.g., peripheral neuropathy, schizophrenia) * History of fainting or seizures * History of frostbite
Contact & Investigator
Roland PEYRON, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Saint Etienne
Frequently Asked Questions
Who can join the NCT04423874 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04423874 currently recruiting?
Yes, NCT04423874 is actively recruiting participants. Contact the research team at roland.peyron@chu-st-etienne.fr for enrollment information.
Where is the NCT04423874 trial being conducted?
This trial is being conducted at Saint-Etienne, France.
Who is sponsoring the NCT04423874 clinical trial?
NCT04423874 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Roland PEYRON, MD at Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 104 participants.